4527 ROHTO PHARMACEUTICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4527

TSE Prime

ROHTO PHARMACEUTICAL CO.,LTD.

2,395.0

JPY

+64.0

(+2.75%)

Mar 13, 3:30 pm JST

15.02

USD

Mar 13, 2:30 am EDT

Result

PTS

outside of trading hours

2,409

Mar 13, 10:14 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	199,646	29,015	28,750	21,127	92.6	18	May 12, 2022	J-GAAP
Mar, 2023	238,664	33,959	35,568	26,377	115.6	22	May 12, 2023	J-GAAP
Mar, 2024	270,840	40,048	42,434	30,936	135.6	27	May 13, 2024	J-GAAP
Mar, 2025	308,625	38,939	40,430	31,006	136.1	36	May 13, 2025	J-GAAP
Mar, 2026 Guidance	340,500	40,500	46,500	33,000	146.0	44	Feb 12, 2026	J-GAAP
YoY	+10.3%	+4.0%	+15.0%	+6.4%	+7.3%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 12, 2020	183,000	21,800	22,100	14,000	13.5	J-GAAP
Results	May 12, 2021	181,287	22,990	23,910	16,743	14	J-GAAP
Mar, 2022	May 12, 2021	Available in future release
	Nov 11, 2021
	Feb 10, 2022
Results	May 12, 2022
Mar, 2023	May 12, 2022
	Aug 9, 2022
	Nov 10, 2022
	Feb 13, 2023
Results	May 12, 2023
Mar, 2024	May 12, 2023
	Aug 9, 2023
	Nov 10, 2023
	Feb 9, 2024
Results	May 13, 2024
Mar, 2025	May 13, 2024
	Aug 7, 2024
	Feb 12, 2025
Results	May 13, 2025
Mar, 2026	May 13, 2025	334,500	39,000	40,500	31,100	42	J-GAAP
	Aug 6, 2025	334,500	39,000	43,000	31,500	42	J-GAAP
	Nov 13, 2025	338,500	39,500	44,000	32,000	43	J-GAAP
	Feb 12, 2026	340,500	40,500	46,500	33,000	44	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	59,503	+6.8	Available in future release
Mar, 2002	62,941	+5.8
Mar, 2003	65,923	+4.7
Mar, 2004	67,378	+2.2
Mar, 2005	73,331	+8.8
Mar, 2006	85,854	+17.1
Mar, 2007	95,619	+11.4
Mar, 2008	108,131	+13.1
Mar, 2009	110,611	+2.3
Mar, 2010	113,429	+2.5
Mar, 2011	115,472	+1.8
Mar, 2012	120,292	+4.2
Mar, 2013	129,146	+7.4
Mar, 2014	143,822	+11.4
Mar, 2015	151,774	+5.5
Mar, 2016	167,016	+10.0
Mar, 2017	154,599	-7.4
Mar, 2018	171,742	+11.1
Mar, 2019	183,582	+6.9
Mar, 2020	188,327	+2.6
Mar, 2021	181,287	-3.7
Mar, 2022	199,646	+10.1
Mar, 2023	238,664	+19.5
Mar, 2024	270,840	+13.5
Mar, 2025	308,625	+14.0
Mar, 2026 Guidance	340,500	+10.3	40,500	+4.0	46,500	+15.0	146.0	+7.3

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	270,840	40,048	14.8	13.59	9.43	0.83	135.6
Mar, 2025	308,625	38,939	12.6	12.18	7.92	0.79	136.1
Mar, 2026 Guidance	340,500	40,500	11.9	11.50	7.16	0.74	146.0

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	308,625	40,048	42,434	31,006	136.1
Fiscal Year	Mar, 2025	Mar, 2024	Mar, 2024	Mar, 2025	Mar, 2025

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	128,351	17,690	17,605	13,185	57.8	12	May 12, 2023	J-GAAP
Oct - Mar, 2023	142,971	19,082	19,756	14,342	62.9	15	May 13, 2024	J-GAAP
Oct - Mar, 2024	169,543	21,148	21,840	18,085	79.4	20	May 13, 2025	J-GAAP
Oct - Mar, 2025 Guidance	176,243	21,183	21,891	15,348	67.9	23	Feb 12, 2026	J-GAAP
YoY	+4.0%	+0.2%	+0.2%	-15.1%	-14.4%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	33,959	17,748	30,924	-13,176	-16,199	77,691	25.09	J-GAAP
Mar, 2024	40,048	17,928	34,245	-16,317	-13,784	86,562	25.01	J-GAAP
Mar, 2025	38,939	-52,253	36,917	-89,170	35,319	73,221	16.75	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2023	201,163	35,262	37,247	26,157	114.7	87.8	Feb 9, 2024	J-GAAP
Apr - Dec, 2024	225,895	31,960	33,076	24,744	108.5	81.8	Feb 12, 2025	J-GAAP
Apr - Dec, 2025	253,071	33,575	39,852	28,279	125.2	85.7	Feb 12, 2026	J-GAAP
YoY	+12.0%	+5.1%	+20.5%	+14.3%	+15.4%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	69,677	4,786	5,187	4,779	21.0	6.9	May 13, 2024	J-GAAP
Apr - Jun, 2024	68,356	11,790	12,273	8,482	37.2	17.2	Aug 7, 2024	J-GAAP
Jul - Sep, 2024	70,726	6,001	6,317	4,439	19.5	8.5	Nov 13, 2024	J-GAAP
Oct - Dec, 2024	86,813	14,169	14,486	11,823	51.8	16.3	Feb 12, 2025	J-GAAP
Jan - Mar, 2025	82,730	6,979	7,354	6,262	27.5	8.4	May 13, 2025	J-GAAP
Apr - Jun, 2025	81,964	11,699	16,127	11,769	52.1	14.3	Aug 6, 2025	J-GAAP
Jul - Sep, 2025	82,293	7,618	8,482	5,883	26.0	9.3	Nov 13, 2025	J-GAAP
Oct - Dec, 2025	88,814	14,258	15,243	10,627	47.0	16.1	Feb 12, 2026	J-GAAP
YoY	+2.3%	+0.6%	+5.2%	-10.1%	-9.2%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	51,676	+2.9	Available in future release
Apr - Jun, 2021	42,315	+9.5
Jul - Sep, 2021	48,704	+9.8
Oct - Dec, 2021	53,003	+13.7
Jan - Mar, 2022	55,624	+7.6
Apr - Jun, 2022	52,255	+23.5
Jul - Sep, 2022	58,058	+19.2
Oct - Dec, 2022	65,950	+24.4
Jan - Mar, 2023	62,401	+12.2
Apr - Jun, 2023	61,171	+17.1
Jul - Sep, 2023	66,698	+14.9
Oct - Dec, 2023	73,294	+11.1
Jan - Mar, 2024	69,677	+11.7
Apr - Jun, 2024	68,356	+11.7
Jul - Sep, 2024	70,726	+6.0
Oct - Dec, 2024	86,813	+18.4
Jan - Mar, 2025	82,730	+18.7
Apr - Jun, 2025	81,964	+19.9
Jul - Sep, 2025	82,293	+16.4
Oct - Dec, 2025	88,814	+2.3	14,258	+0.6	15,243	+5.2	47.0	-9.3

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	88,814	14,296	16,127	11,823	52.1
Fiscal Year	Dec, 2025	Dec, 2023	Jun, 2025	Dec, 2024	Jun, 2025

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	916.93	67.6	309,677	209,187	184,005	0.06	May 12, 2023	J-GAAP
Mar, 2024	1,078.04	71.0	346,175	245,942	209,399	0.04	May 13, 2024	J-GAAP
Mar, 2025	1,149.35	60.2	437,039	262,990	231,713	0.19	May 13, 2025	J-GAAP
Apr - Dec, 2025	ー	62.3	460,668	287,074	250,635	0.18	Feb 12, 2026	J-GAAP

ROHTO PHARMACEUTICAL CO.,LTD.(4527) Financial Results